Shares in Racura Oncology Ltd (ASX: RAC) have jumped more than 10% in early trade after the company announced the successful first dosing of a patient in Hong Kong with its RC220 cancer compound.
The company said in a statement to the ASX that the patient was the third to be dosed with the compound, but the first at the Hong Kong Site.
Good early signs
Racura said no vein inflammation or other adverse events were reported following the dosing, and to date, no dose-limiting toxicities have been observed in any of the three patients dosed.
The company added:
Dosing of the third patient also completes recruitment of the first trial cohort. In accordance with the trial protocol, the Safety Review Committee (SRC) will review all accumulated safety data collected from the three patients. Subject to SRC review and clearance, the trial will then progress to the next planned RC220 dose level of 80 mg/m2 using the updated trial protocol announced 11 February 2026.
Racura Chief Executive Officer Dr Daniel Tillett said on Thursday:
The safe dosing of the third patient in our RC220 solid tumour trial in Hong Kong and recruitment of the first dose escalation cohort is an important milestone for Racura Oncology. We are grateful to all the patients, investigators, and clinical teams who have made this trial possible and we look forward to treating patients on the updated protocol.
Stage 1 of the RC220 trial will be carried out across Australia, Hong Kong, and South Korea, and involves ascending doses “to determine the safety, tolerability, pharmacokinetics, and maximum tolerated combined dose of RC220 in combination with doxorubicin in up to 33 patients”.
After interim analysis of the data, another 20 patients will be administered the compound to test for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals, Racura said.
Multiple uses being examined
Racura said in its statement to the ASX that RC220 was being tested to address the high unmet needs of patients across multiple cancer indications with a Phase 3 clinical program in acute myeloid leukemia, a Phase 1a/b program in lung cancer, and the trial mentioned previously, which aims to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
The ASX biotech’s shares traded as high as $2.73 on the news, up 14.7%, before settling back to be 8.8% higher at $2.57.
Racura was valued at $433 million at the close of trade on Wednesday.
The post Which ASX biotech’s shares have jumped more than 10% on positive clinical trial news? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Racura Oncology right now?
Before you buy Racura Oncology shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Racura Oncology wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today?
- Charter Hall Long WALE REIT declares March 2026 distribution and DRP update
- If a 30-year-old invests $500 a month in ASX stocks, here’s what they could have by retirement
- 2 great ASX 200 blue-chip shares I’d buy right now
- Why Boss Energy shares are falling despite positive uranium update
Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.